Cross-immunity against SARS-COV-2 variants of concern in naturally infected critically ill COVID-19 patients
Douglas D. Fraser(Western University), Brian Webb(Thermo Fisher Scientific (United States)), Markus Miholits, Michael R. Miller(Western University), Gediminas Cepinskas(Western University), Susanne Oehler(Lawson Health Research Institute), Claudio M. Martin(Western University), Marat Slessarev(Western University), Alison Fox‐Robichaud, Mark Daley(Western University), Maitray A. Patel(Western University), Logan R. Van Nynatten(Western University), Sigrun Badrnya, Ganeem K. Juneja(Thrombosis and Atherosclerosis Research Institute), Paul Y. Kim(McMaster University Medical Centre), Shannon Seney(Lawson Health Research Institute), Calvin H. Yeh(Athinoula A. Martinos Center for Biomedical Imaging), Vanessa Sabourin(Thrombosis and Atherosclerosis Research Institute)
Cited by 6
Related Papers
A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care
|New England Journal of Medicine|1999|5.2k
DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?
|Clinical Infectious Diseases|2014|1.1k
Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study
|Intensive Care Medicine|2001|984
Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases?
|Critical Care Medicine|2001|597